Syndax Pharmaceuticals Cash Flow Statement
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.99+0.09 (+0.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals free cash flow
In fiscal 2025, Syndax Pharmaceuticals generated -$323.0 million of operating cash flow and spent $187,000 on capital expenditures. That left free cash flow of -$323.2 million, a free-cash-flow margin of -187.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -285.42M | -318.76M | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M |
| Net Income growth (YoY) | — | — | — | -699.13% | — | — | — | — | — | — |
| Depreciation & Amortization | 6.00M | 8.00M | 12.00M | 33.00M | 43.00M | 90.00K | 92.00K | 78.00K | 76.00K | 89.00K |
| Stock-Based Compensation | 47.50M | 43.03M | 30.95M | 16.02M | 13.32M | 9.06M | 6.00M | 6.20M | 5.45M | 4.71M |
| Change in Working Capital | -72.07M | -5.84M | 5.61M | -1.32M | -12.37M | -8.50M | 3.17M | -1.28M | 2.37M | -1.93M |
| Operating Cash Flow | -322.98M | -274.90M | -160.60M | -133.68M | 29.13M | -71.26M | -50.61M | -68.53M | -47.37M | -35.16M |
| Capital Expenditures | -187.00K | 0 | 0 | 0 | -129.00K | 0 | — | -187.00K | -84.00K | -261.00K |
| Investing Cash Flow | 290.04M | -219.78M | 117.61M | -186.19M | -40.87M | -142.53M | 12.78M | 51.40M | -17.07M | -18.28M |
| Debt Issued | — | — | — | 0 | 0 | 19.73M | — | — | — | — |
| Financing Cash Flow | 13.68M | 353.37M | 264.13M | 172.25M | 118.46M | 304.42M | 28.57M | 15.73M | 75.72M | 54.20M |
| Net Change in Cash | -19.27M | -141.31M | 221.14M | -147.61M | 106.72M | 90.63M | -9.26M | -1.40M | 11.28M | 762.00K |
| Free Cash Flow | -323.17M | -274.90M | -160.60M | -133.68M | 29.00M | -71.26M | -50.61M | -68.72M | -47.45M | -35.42M |
This table shows 10 annual periods of Syndax Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a cash flow statement?